PF 514273
Alternative Names: PF-514273Latest Information Update: 10 Mar 2008
At a glance
- Originator Pfizer
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 28 Feb 2008 Discontinued - Phase-I for Obesity in USA (unspecified route)